KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Change in Accured Expenses (2016 - 2025)

Amgen (AMGN) has 17 years of Change in Accured Expenses data on record, last reported at -$76.0 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 110.44% year-over-year to -$76.0 million; the TTM value through Dec 2025 reached -$156.0 million, down 269.57%, while the annual FY2025 figure was -$156.0 million, 269.57% down from the prior year.
  • Change in Accured Expenses reached -$76.0 million in Q4 2025 per AMGN's latest filing, down from -$10.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $728.0 million in Q4 2024 and bottomed at -$603.0 million in Q3 2024.
  • Average Change in Accured Expenses over 5 years is -$11.8 million, with a median of -$66.0 million recorded in 2024.
  • Peak YoY movement for Change in Accured Expenses: tumbled 487.5% in 2021, then soared 350.17% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$267.0 million in 2021, then plummeted by 37.08% to -$366.0 million in 2022, then increased by 20.49% to -$291.0 million in 2023, then skyrocketed by 350.17% to $728.0 million in 2024, then plummeted by 110.44% to -$76.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$76.0 million in Q4 2025, -$10.0 million in Q3 2025, and $8.0 million in Q2 2025.